Article thumbnail

Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy

By Kenichi Watanabe, Rajarajan A Thandavarayan, Meilei Harima, Flori R Sari, Narasimman Gurusamy, Punniyakoti T Veeraveedu, Sayaka Mito, Wawaimuli Arozal, Vijayakumar Sukumaran, Arun Prasath Laksmanan, Vivian Soetikno, Makoto Kodama and Yoshifusa Aizawa

Abstract

Diabetes mellitus increases the risk of heart failure independently of underlying coronary artery disease, and many believe that diabetes leads to cardiomyopathy. The underlying pathogenesis is partially understood. Several factors may contribute to the development of cardiac dysfunction in the absence of coronary artery disease in diabetes mellitus. There is growing evidence that excess generation of highly reactive free radicals, largely due to hyperglycemia, causes oxidative stress, which further exacerbates the development and progression of diabetes and its complications. Hyperglycemia-induced oxidative stress is a major risk factor for the development of micro-vascular pathogenesis in the diabetic myocardium, which results in myocardial cell death, hypertrophy, fibrosis, abnormalities of calcium homeostasis and endothelial dysfunction. Diabetes-mediated biochemical changes show cross-interaction and complex interplay culminating in the activation of several intracellular signaling molecules. Diabetic cardiomyopathy is characterized by morphologic and structural changes in the myocardium and coronary vasculature mediated by the activation of various signaling pathways. This review focuses on the oxidative stress and signaling pathways in the pathogenesis of the cardiovascular complications of diabetes, which underlie the development and progression of diabetic cardiomyopathy

Topics: Article
Publisher: Bentham Science Publishers Ltd
OAI identifier: oai:pubmedcentral.nih.gov:3083809
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). 14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. Biochem Pharmacol
  2. (2000). A conserved docking motif in MAP kinases common to substrates, activators and regulators.
  3. (2003). A critical role for PPARalphamediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.
  4. (1997). A cytoplasmic inhibitor of the JNK signal transduction pathway. Science
  5. (1999). Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes
  6. (1999). Abnormal cardiac function in the streptozotocin-induced non-insulin-dependent diabetic rat: noninvasive assessment with doppler echocardiography and contribution of the nitric oxide pathway.
  7. (2001). Abnormal myocardial free fatty acid utilization deteriorates with morphological changes in the hypertensive heart. Jpn Circ J
  8. (2002). Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.
  9. (1999). Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease.
  10. (2000). Activation of members of the mitogen-activated protein kinase family by glucose in endothelial cells.
  11. (1998). Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo. Circulation
  12. (2004). Adrenomedullin protects against myocardial apoptosis after ischemia/reperfusion through activation of AktGSK signaling. Hypertension
  13. (1983). Alterations in Ca2+ binding by and composition of the cardiac sarcolemmal membrane in chronic diabetes.
  14. (1987). Alterations in cardiac sarcolemmal Ca2+ pump activity during diabetes mellitus.
  15. (2006). Altered calcium handling is an early sign of streptozotocin-induced diabetic cardiomyopathy.
  16. (2000). Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice.
  17. (2000). Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes.
  18. (1996). Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science
  19. (1997). Analysis of activation-induced conformational changes in p47phox using tryptophan fluorescence spectroscopy.
  20. (1997). Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension
  21. (1997). Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts.
  22. (1996). Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
  23. (2004). Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
  24. (1999). Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats. Temporal regulation and spatial heterogeneity. Hypertension
  25. (2000). Apoptosis in the erectile tissues of diabetic and healthy rats.
  26. (2000). Apoptosis is initiated by myocardial ischemia and executed during reperfusion.
  27. (2000). Apoptosis signal-regulating kinase 1 (ASK1) induces neuronal differentiation and survival of PC12 cells.
  28. (2000). Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism. Urol Res
  29. (2001). ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep
  30. (2003). AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension
  31. (2003). Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res
  32. (1997). c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis.
  33. (2000). CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.
  34. (2002). Cardiac microtubules are more resistant to chemical depolymerisation in streptozotocin-induced diabetes in the rat. Pflugers Arch
  35. (2002). Cardiovascular function in patients with insulin-dependent diabetes mellitus: a study using noninvasive methods.
  36. (2003). Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. Clin Sci (Lond)
  37. (1996). CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases. Oncogene
  38. (2003). Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol
  39. (1989). Cellular origin and distribution of transforming growth factor-beta in the normal rat myocardium. Cell Tissue Res
  40. (1988). Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res
  41. (2001). Characterization of contractile function in diabetic hypertensive cardiomyopathy in adult rat ventricular myocytes.
  42. (1997). Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats.
  43. (1994). Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes
  44. (1993). Collagen remodelling in myocardia of patients with diabetes.
  45. (1993). Correlation between metabolic and histopathological changes in the myocardium of the KK mouse. Effect of diltiazem on the diabetic heart. Jpn Heart J
  46. (1981). Depressed cardiac sarcoplasmic reticular function from diabetic rats.
  47. (1999). Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J
  48. (1980). Diabetes mellitus induces changes in cardiac myosin of the rat. Diabetes
  49. (1999). Diabetic cardiomyopathy and carnitine deficiency.
  50. (2004). Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev
  51. (1995). Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care
  52. (1998). Diabetic cardiomyopathy. Clin Cardiol
  53. (1988). Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography.
  54. (2001). Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care
  55. (1999). Differential effects of angiotensin II receptor blockade on pressureinduced left ventricular hypertrophy and fibrosis in rats.
  56. (1998). Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1.
  57. (2004). Dominant negative 14-3-3 promotes cardiomyocyte apoptosis in early stage of type I diabetes mellitus through activation of JNK.
  58. (2002). Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes: a case for gender difference. Diabetes Care
  59. (2002). Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice.
  60. (2001). Echocardiographic characterization of fundamental mechanisms of abnormal diastolic filling in diabetic rats with a parameterized diastolic filling formalism.
  61. (1982). Echocardiographic evidence for impaired myocardial performance in children with type I diabetes mellitus.
  62. (1993). Effects of diabetes on myocardial glucose transport system in rats: implications for diabetic cardiomyopathy.
  63. Embryonic gene expression patterns of TGF beta 1, beta 2 and beta 3 suggest different developmental functions in vivo.
  64. (1990). Evidence against the involvement of nonenzymatic glycosylation in diabetic cardiomyopathy. Metabolism
  65. (1977). Evidence for cardiomyopathy in familial diabetes mellitus.
  66. (1984). Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy).
  67. (2002). Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade. Cardiovasc Pathol
  68. (2002). Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes
  69. (1997). Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates.
  70. (1990). Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes.
  71. (1995). Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol
  72. (1988). Glycation of proteins as a source of superoxide. Diabete Metab
  73. (2005). Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol
  74. (2006). Glycogen synthase kinase 3beta together with 14-3-3 protein regulates diabetic cardiomyopathy: effect of losartan and tempol.
  75. (1996). Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin IIinduced hypertrophy in vascular smooth muscle cells.
  76. (1970). Haemodynamic studies on newly diagnosed diabetics before and after adequate insulin treatment.
  77. (1985). Heart mitochondrial function in chronic experimental diabetes in rats.
  78. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes
  79. (2000). High glucoseinduced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation
  80. (2002). Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes
  81. (2002). Hyperglycemiainduced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes
  82. (1993). Hyperglycemic pseudohypoxia and diabetic complications. Diabetes
  83. (2001). IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes
  84. (2005). Inactivation of 14-3-3 protein exacerbates cardiac hypertrophy and fibrosis through enhanced expression of protein kinase C beta 2 in experimental diabetes. Biol Pharm Bull
  85. (1999). Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation
  86. (2003). Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med
  87. (2003). Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol
  88. (1991). Influence of experimental diabetes on sarcoplasmic reticulum function in rat ventricular muscle.
  89. (1996). Inhibition of angiotensin type 1 receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes
  90. (1990). Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans
  91. (1999). Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res
  92. (2003). Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes
  93. (2001). Involvement of 1,2-diacylglycerol in improvement of heart function by etomoxir in diabetic rats. Life Sci
  94. (2000). Involvement of a p38 mitogenactivated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia.
  95. (1989). Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res
  96. (2005). Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways.
  97. (2002). Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats.
  98. (2010). Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-9. Role of Differential Signaling Pathways and Oxidative Current Cardiology Reviews,
  99. (2000). Lipotoxic heart disease in obese rats: implications for human obesity.
  100. (2002). Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J
  101. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res
  102. (1998). Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem
  103. (1996). Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart.
  104. (1996). Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat heart.
  105. (1997). Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes
  106. (2003). Mitogenactivated protein kinases in the acute diabetic myocardium. Mol Cell Biochem
  107. (2001). Molecular and cellular mechanisms of cardiotoxicity. Environ Health Perspect
  108. (1995). Molecular mechanism of cardiac cellular hypertrophy by mechanical stress.
  109. (2001). mRNA and activities are increased in early diabetic glomeruli. Kidney Int
  110. (2000). Myocardial cell death in human diabetes. Circ Res
  111. (1995). Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET.
  112. (2000). Myocyte death in streptozotocininduced diabetes in rats in angiotensin II- dependent. Lab Invest
  113. (1999). Myocyte death in the failing human heart is gender dependent. Circ Res
  114. (2000). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res
  115. (1972). New type of cardiomyopathy associated with diabetic glomerulosclerosis.
  116. (1999). Noninvasive evaluation of cardiac dysfunction by echocardiography in streptozotocin-induced diabetic rats.
  117. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.
  118. (1996). Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature
  119. (2001). Overexpression of manganese superoxide dismutase suppresses increases in collagen accumulation induced by culture of mesangial cells in high-media glucose. Metabolism
  120. (2002). Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes
  121. (2002). Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and prooxidants.
  122. (2001). Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol
  123. (1996). Oxidative stress and diabetic vascular complications. Diabetes Care
  124. (1998). Oxidative stress measurement by in vivo electron spin resonance spectroscopy in rats with streptozotocin-induced diabetes. Diabetologia
  125. (2000). p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta -adrenergic receptor-stimulated apoptosis. Evidence for Gidependent activation.
  126. (1992). Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation.
  127. (2000). Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart.
  128. (1991). Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med
  129. (1998). Protein kinase C activation and the development of diabetic complications. Diabetes
  130. (2001). Protein kinase C activation: isozymespecific effects on metabolism and cardiovascular complications in diabetes. Diabetologia
  131. (1992). Protein kinase C activity is altered in diabetic rat hearts.
  132. (1995). Protein kinase C isoform diversity in the heart.
  133. (2003). Protein kinase Cdependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase.
  134. (1994). Quantitative analysis of myocardial structure in insulin-dependent diabetes mellitus: effects of immediate and delayed insulin replacement.
  135. (1985). Quantitative approach to the histopathology of the biopsied right ventricular myocardium in patients with diabetes mellitus. Heart Vessels
  136. (2005). Redox regulation of Ito remodeling in diabetic rat heart.
  137. (2004). Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol Cell Biochem
  138. (2004). Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes
  139. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes
  140. (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes
  141. (2004). Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.
  142. (1983). Sarcolemmal Na+-K+-ATPase activity in diabetic rat heart.
  143. (2000). Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev
  144. (1999). Signaling pathways for cardiac hypertrophy and failure.
  145. (2000). Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress. Kidney Int
  146. (1985). Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis
  147. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell
  148. (1998). Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors.
  149. (1997). Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy.
  150. (1997). The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol
  151. (1992). The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res
  152. (1984). The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes
  153. (2001). The influence of gender, diabetes, and acetaldehyde on the intrinsic contractile properties of isolated rat myocardium. Cardiovasc Toxicol
  154. (2001). The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res
  155. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes
  156. (1996). The role of cJun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation.
  157. (1987). The role of coronary artery lesions in ischemic heart disease: insights from recent clinicopathologic, coronary arteriographic, and experimental studies. Hum Pathol
  158. (1995). The TGF beta superfamily in myocardium: ligands, receptors, transduction, and function.
  159. (2001). Transmural heterogeneity of myocardial integrated backscatter in diabetic patients without overt cardiac disease. Diabetes Res Clin Pract
  160. (2003). Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes. Physiol Genomics
  161. (1994). Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care